Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease
Recruiting now · Phase 4
Conditions studied: Portal Hypertension, Hepatic Decompensation, Advanced Chronic Liver Disease
In brief
The goal of this randomised controlled trial is to evaluate the effect of carvedilol (a non-selective beta-blocker) in patients with compensated advanced chronic liver disease under clinically significant portal hypertension or the grey zone of Baveno VII criteria. The main question it aims to answer is: Does carvedilol reduce hepatic decompensation and mortality in these patients despite the absence of varices needing treatment. Researchers will compare carvedilol to no carvedilol to see if carvedilol can prevent hepatic decompensation and mortality. Participants will either take carvedilol or not taking carvedilol for 5 years with regular clinic visit for checkups and investigations, including blood tests, ultrasonography of the liver, upper gastrointestinal endoscopy, transient elastography.
Key facts
- Study ID
- NCT06449339
- Run by
- Chinese University of Hong Kong
- People needed
- 474
- Starts
- 2024-07-17
- Expected to finish
- 2031-07-30
- Last updated by the study team
- 2025-06-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Aged 18 years of above
- Established diagnosis of chronic liver disease(s) of the following etiologies
- Alcohol-related liver disease (ARLD)
- Chronic hepatitis B (CHB)
- Chronic hepatitis C (CHC)
- Metabolic dysfunction-associated steatotic liver disease (MASLD) § Non-obese (BMI <30kg/m2) and obese (BMI ≥30 kg/m2)
- In high-risk grey zone or CSPH, by Baveno VII criteria (for ARLD, CHB, CHC and non-obese MASLD) or ANTICIPATE-NASH model (for obese MASLD) within 6 months from screening
- Baveno VII criteria (for ARLD, CHB, CHC and non-obese MASLD)
- LSM ≥25 kPa (CSPH)
- LSM ≥20 kPa - <25 kPa and platelet count <150 x 10\^9/L; or LSM ≥15 kPa - <20 kPa and platelet count <110 x 10\^9/L (high-risk grey zone)
- ANTICIPATE-NASH model (for obese MASLD)
- Predictive probability for CSPH >90% (CSPH)
- Predictive probability for CSPH ≥60% - <90% (high-risk grey zone)
You may not qualify if…
- Presence of high-risk varices (HRV) (i.e. moderate to large oesophageal varices [OV] or OV with red wale sign) found in OGD
- Current use of non-selective beta-blocker (NSBB) or any use of NSBB within 6 months before
- Use of selective beta blocker, such as atenolol or metoprolol, is not excluded
- Selective beta-blocker will be switched to carvedilol in NSBB arm, and will be kept unchanged in conventional arm if there is clinical need for the selective beta-blocker
- Contraindication to NSBB (e.g. Type II/III heart block or baseline bradycardia <60/minute, hypotension with systolic blood pressure (SBP) <100 mmHg, asthma, poorly controlled chronic obstructive pulmonary disease, and peripheral vascular disease)
- Current use of nitrated drugs or any use of nitrated drugs within 6 months before
- o Use of sublingual nitrate, such as glyceryl trinitrate, is not excluded
- Contraindication to OGD (e.g. Intestinal perforation or obstruction)
- Current or history of decompensated liver cirrhosis (i.e. Child's C cirrhosis, prior decompensating events such as ascites, variceal bleeding, hepatic encephalopathy and hepatorenal syndrome)
- o Child's B cirrhosis without decompensating events is not excluded
- Current or history of hepatocellular carcinoma (HCC)
- Current or history of portal vein thrombosis
- Transjugular intrahepatic portosystemic shunt (TIPS)
- Liver transplantation
- Serious medical illness with limited life expectancy of less than 6 months
- Pregnancy
- Unable to obtain or refusal of informed consent from patient
Where it is running
- Prince of Wales Hospital, The Chinese University of Hong Kong — Hong Kong, Hong Kong (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.